- Biophytis and LynxKite are introducing new approaches beyond the MASSIVE project, utilizing AI for the discovery of next-generation longevity therapies.
- This collaboration will generate revenue through:
- A computational platform focused on longevity, featuring unique curated datasets and accelerated computation methods relevant to longevity research.
- The development of next-generation drug candidates for sarcopenia.
- The development of next-generation drug candidates for dry age-related macular degeneration.
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 — LynxKite is expanding its collaboration with Biophytis SA (Euronext Growth Paris: ALBPS) (“Biophytis”), initially through the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for Sarcopenia therapy), with plans to extend the platform to other therapeutic areas. This strategic initiative, also supported by Enterprise Singapore, aligns with key focus areas of Singapore’s Research, Innovation and Enterprise (RIE) 2030 plan.
LynxKite Technologies, a leader in advanced analytics and artificial intelligence recognized for its open-source platform LynxKite, will incorporate AI computational methods pertinent to longevity research into its computational orchestration platform. With over a decade of experience, LynxKite’s founding team has assisted more than 100 global organizations, including prominent companies like Roche, AstraZeneca, and Hummingbird Biosciences, in analyzing complex data through graph-based and generative AI methodologies.
The initial MASSIVE project is designed to identify and develop Mas receptor (MasR) activator drug candidates targeting sarcopenia, a progressive muscle disease linked to aging that impacts millions of elderly individuals globally. Biophytis contributes its extensive knowledge in age-related diseases, its preclinical experience with MasR-related indications, and its expertise in Mas receptor pharmacology. LynxKite provides cutting-edge AI technologies, chemoinformatics, and software engineering, complemented by scalable GPU computation utilizing the latest NVIDIA toolkits and cloud platforms such as Nebius. Together, the partners are enhancing Biophytis’ strategic drug discovery program, supporting its longevity-focused strategy and market positioning.
The primary objectives of this project include:
- Developing a model of the Mas receptor for structure-based drug design using AI and protein prediction tools.
- Designing and prioritizing synthetic drug candidates through AI-driven molecule generation and predictive filtering.
- Synthesizing and evaluating promising MasR activators to assess their biological activity, safety, and pharmacokinetic properties.
- Identifying and protecting the lead candidate through patent applications in preparation for preclinical development.
- Developing and validating the AI software through iterative feedback from *in vitro* and *in vivo* validation of the candidates.
“The initiation of MASSIVE represents a significant advancement in our longevity strategy, merging our clinical expertise with LynxKite’s innovative AI to expedite the discovery of groundbreaking therapies for sarcopenia,” stated Stanislas Veillet, CEO of Biophytis.
Gyorgy Lajtai, CEO of LynxKite, commented, “We are honored to partner with Biophytis in pioneering computational longevity through our LynxKite platform, demonstrating how LynxKite can transform discovery by designing, integrating, and orchestrating relevant computational tools across various modalities.”
About LynxKite
LynxKite Technologies Pte Ltd, headquartered in Singapore with operations in the United States and Switzerland, offers the LynxKite platform. This platform integrates graph analytics and biological language models while managing, optimizing, and auto-scaling GPU resources for efficient execution of complex pipelines, such as NVIDIA NIM Microservices. Building on over a decade of experience in graph and enterprise AI, LynxKite collaborates with research institutions, technology partners, and industry leaders to accelerate scientific discovery and advanced analytics. Further details are available at https://lynxkite.com.
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company dedicated to developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), its lead drug candidate, is a small molecule undergoing development for muscle diseases (sarcopenia, Phase 3 ready) and metabolic disorders (obesity, Phase 2 ready). The company is based in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Biophytis’ ordinary shares are traded on Euronext Growth Paris (ALBPS – FR001400OLP5), and its American Depositary Shares (ADS) are listed on the OTC market (BPTSY – US 09076G401). More information can be found at www.biophytis.com.
About Nebius
Nebius, an AI cloud company, is developing a comprehensive platform for developers and businesses to control their AI future, from data and model training to production deployment. Founded on extensive in-house technological expertise and operating at scale with a growing global presence, Nebius serves startups and enterprises worldwide that are building AI products, agents, and services. Nebius is listed on Nasdaq (NASDAQ: NBIS) and is headquartered in Amsterdam. For more information, please visit www.nebius.com.
SOURCE Biophytis; LynxKite Technologies